Clinical trials: CVC
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.
- Trial name
- NCT02342067
- Testing
- Cenicriviroc, Pioglitazone
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
HIV-infection/AIDS
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.
- Trial name
- NCT01827540
- Testing
- Cenicriviroc, Dolutegravir, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
This is a Phase 1, Open-Label, 3-Period, Single-sequence, Drug-drug Interaction Study in Healthy Subjects to Assess the Effect of Cenicriviroc on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors [Rosuvastatin (ROS)…
- Trial name
- NCT02685462
- Testing
- Rosuvastatin, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Liver Insufficiency
Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment
To determine whether CVC exposures are altered in subjects with impaired hepatic function, compared to subjects with normal hepatic function.
- Trial name
- NCT02120547
- Testing
- Cenicriviroc in mild liver impaired, Cenicriviroc in moderate liver impaired
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
Healthy
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
- Trial name
- NCT02684799
- Testing
- Cenicriviroc, Omeprazole, Famotidine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.